## Summary of the kidney review

- Extensive background and experimental systems for kidney heart and liver rejection

   Extensive annotation of gene changes as transcript sets.
- 2. Analytical tools, including cross validation and archetypal analysis.
- 3. Gene expression changes in herds need Classifiers
- 4. Molecular landscape.
  - a. Top Genes and pathways reveal the biology.
- 5. Archetypal analysis of rejection currently identifies six states
- 6. Molecular features of recent parenchymal increased injury and of atrophy fibrosis.
- 7. The report
  - a. Discrepancies: Agreement with histology is limited to some extent by the noise in histology and inter-observer disagreement.
- 8. Recent and ongoing developments
  - a. Time course.
  - b. What does rejection do to parenchymal injury.
  - c. No adherence. Survival. DSA negative ABMR.
  - d. What lies beneath: subtle ABMR
- 9. Dissecting kidney injury and its relationship to function and survival.
- 10. dd-cfDNA correlates with active ABMR.
- 11. An integrated view

## Key references

1. Madill-Thomsen KS, Bohmig GA, Bromberg J, Einecke G, Eskandary F, Gupta G, et al. Relating molecular T cell-mediated rejection activity in kidney transplant biopsies to time and to histologic tubulitis and atrophy-fibrosis. Transplantation 2022;107(5):1102-1114.

2. Halloran PF, Madill-Thomsen KS, Pon S, Sikosana MLN, Bohmig GA, Bromberg J, et al. Molecular diagnosis of ABMR with or without donor-specific antibody in kidney transplant biopsies: differences in timing and intensity but similar mechanisms and outcomes Am J Transplant. 2022;22(8):1976-91.

3. Halloran PF, Böhmig GA, Bromberg J, Einecke G, Eskandary FA, Gupta G, et al. Archetypal Analysis of Injury in Kidney Transplant Biopsies Identifies Two Classes of Early AKI. Frontiers in Medicine. 2022;9(Article 817324):1-12.

4. Madill-Thomsen KS, Bohmig GA, Bromberg J, Einecke G, Eskandary F, Gupta G, et al. Donor-Specific Antibody Is Associated with Increased Expression of Rejection Transcripts in Renal Transplant Biopsies Classified as No Rejection. J Am Soc Nephrol. 2021;32(11):2743-58.

5. Halloran PF, Reeve J, Madill-Thomsen KS, Demko Z, Prewett A, Billings P, et al. The Trifecta Study: Comparing Plasma Levels of Donor-derived Cell-Free DNA with the Molecular Phenotype of Kidney Transplant Biopsies. J Am Soc Nephrol. 2022;33(2):387-400.

6. Halloran PF, Reeve J, Madill-Thomsen KS, Demko Z, Prewett A, Gauthier P, et al. Antibodymediated rejection without detectable donor-specific antibody releases donor-derived cell-free DNA: results from the Trifecta study. Transplantation. 2022;In press.

7. Halloran PF, Reeve J, Madill-Thomsen KS, Kaur N, Ahmed E, Cantos C, et al. Combining donorderived cell-free DNA fraction and quantity to detect kidney transplant rejection using molecular diagnoses and histology as confirmation. Transplantation. 2022;June 29, 2022 - Volume - Issue -10.1097/TP.000000000004212 doi: 10.1097/TP.00000000004212.

8. Halloran PF, Bohmig GA, Bromberg JS, Budde K, Gupta G, Einecke G, et al. Discovering novel injury features in kidney transplant biopsies associated with TCMR and donor aging. Am J Transplant. 2021;21(5):1725-39.

9. Einecke G, Reeve J, Gupta G, Bohmig GA, Eskandary F, Bromberg JS, et al. Factors associated with kidney graft survival in pure antibody-mediated rejection at the time of indication biopsy: Importance of parenchymal injury but not disease activity. Am J Transplant. 2021;21(4):1391-401.

10. Madill-Thomsen K, Perkowska-Ptasinska A, Bohmig GA, Eskandary F, Einecke G, Gupta G, etal. Discrepancy analysis comparing molecular and histology diagnoses in kidney transplant biopsies. Am J Transplant. 2020;20(5):1341-50.

11. Reeve J, Bohmig GA, Eskandary F, Einecke G, Gupta G, Madill-Thomsen K, et al. Generating automated kidney transplant biopsy reports combining molecular measurements with ensembles of machine learning classifiers. Am J Transplant. 2019;19(10):2719-31.

12. Famulski KS, Reeve J, de Freitas DG, Kreepala C, Chang J, Halloran PF. Kidney transplants with progressing chronic diseases express high levels of acute kidney injury transcripts. Am J Transplant. 2013;13(3):634-44.

13. FamulskiKS, de Freitas DG, Kreepala C, Chang J, Sellares J, Sis B, et al. Molecular phenotypes of acute kidney injury in kidney transplants. J Am Soc Nephrol. 2012;23(5):948-58.

14. Reeve J, Bohmig GA, Eskandary F, Einecke G, Lefaucheur C, Loupy A, et al. Assessing rejection-related disease in kidney transplant biopsies based on archetypal analysis of molecular phenotypes. JCI Insight. 2017;2(12):e94197.